Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review
Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review -- Net Revenues Increased Despite COVID-19 Pandemic-Related Challenges -- -- Improved Overall Operating Results and Net Income vs. Net Loss in 2019 -- News provided by Share this article TORRANCE, Calif., May 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed ...